Compare Incyte Corporation (INCY) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Upstart Holdings Inc — how do they compare? Incyte Corporation trades at $117.9 (market cap $23.11B), while Upstart Holdings Inc trades at $29.69 (market cap $2.76B). The key difference: Incyte Corporation is far larger — about 8.4× Upstart Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| INCY | UPST | |
|---|---|---|
Market Cap | $23.11B | $2.76B |
Sector | Health | Financials |
52-Week High | $118.52 | $84.13 |
52-Week Low | $67.38 | $24.22 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Upstart Holdings trades at $28.68, down 2.81% on the day, with a bearish technical signal but oversold RSI levels. The company reported a net income of $53.60M in 2025, a significant improvement from prior losses, though recent Q1 2026 earnings missed expectations. Revenue growth to $1.02B in 2025 and expanding AI lending platform into auto and home loans highlight operational progress.
The stock presents a recovery opportunity with analyst consensus target of $42.00, but faces risks from volatile earnings, high debt levels, and margin pressure. Investor sentiment is mixed amid ongoing execution challenges in a competitive fintech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
